Dietary inflammation, gut microbiome, and muscle loss in older adults
Official title: Exploring the Relationship of Diets Inflammatory, Gut Microbiota, and Sarcopenia: A Cross-Sectional Study
Run by LanZhou University · NCT07211321 · Data updated 2026-11-12
This project will test whether inflammatory features of people's diets are linked to changes in gut bacteria and to muscle loss in community-dwelling adults aged 60 and over.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 60 Years and up |
| Sex | All |
| Enrollment | 1220 (estimated) |
| Sponsor | LanZhou University Academic / other |
| Locations | 1 site (Lanzhou, Gansu) |
| Status | Recruiting |
| Started | April 16, 2024 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | October 7, 2025 |
| Trial ID | NCT07211321 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are community-dwelling adults aged 60 or older who have lived in the community for more than five years and can complete gait, handgrip, and BIA testing and are not taking medications that affect muscle function.
✕Probably not a fit
People with severe mobility or cognitive impairment, cardiac pacemakers, chronic conditions that limit dietary intake, or those taking medications that affect muscle function are unlikely to participate or receive direct benefit from this observational study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This cross-sectional observational project will recruit community-dwelling adults aged 60 and older in Lanzhou and collect dietary information, stool samples for gut microbiota sequencing, and muscle function measures including bioelectrical impedance analysis, gait speed, and handgrip strength. Researchers will calculate a dietary inflammatory index from reported intake and characterize gut microbial diversity and composition using sequencing-based methods. They will analyze associations between dietary inflammatory potential, microbial profiles, and sarcopenia status and test whether gut microbiota features mediate the link between diet-driven inflammation and muscle loss. Participants with pacemakers, severe mobility or cognitive impairment, chronic diseases that limit dietary intake, or medications affecting muscle function will be excluded to ensure reliable measurements.
Why it matters
Potential benefit: If successful, the findings could identify dietary or microbiome targets to help prevent or slow age-related muscle loss.
How similar studies have gone: There is growing evidence linking diet-driven inflammation and the gut microbiota to muscle health, but demonstration of specific microbial mediators of sarcopenia remains an emerging and not-yet-established area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Permanent residents of the community aged 60 years or older. * Continuous residence duration in the community for more than 5 years. Exclusion Criteria: * Taking medications known to affect muscle function (e.g., corticosteroids, protein supplements, muscle enhancers). * Requiring walking assistance or having severe cognitive impairment that would preclude successful completion of assessments including bioelectrical impedance analysis (BIA), gait speed measurement, and handgrip strength testing. * Presence of a cardiac pacemaker, which contraindicates BIA measurement. * Diagnosis of one or more chronic diseases that significantly limit dietary intake.
Where it's running
-
Lanzhou university
Lanzhou, Gansu, China Recruiting
Study contacts
- Study coordinator: Jianhua Ma Doctor of Medicine
- Email: majianhua@lzu.edu.cn
- Phone: 0086 18993157029
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sarcopenia in Patients After Cardiac Surgery
This observational study tests how common sarcopenia is after cardiac surgery and whether current care helps improve muscle mass and function.
-
Bone marrow mesenchymal stem cell injection for sarcopenia
This study tests whether CG-BM1, a stem cell injection, can be safely given to adults with sarcopenia to see if it helps improve muscle health.
-
GLP-1 receptor agonist use and muscle health in adults with obesity without diabetes
This study tests whether GLP-1 receptor agonists affect muscle mass and strength in adults with obesity who don’t have diabetes.
-
Sarcopenia and Epidural Steroid Injections in Lumbar Spinal Stenosis
We’re testing how sarcopenia relates to pain, function, and quality of life after a routine interlaminar epidural steroid injection in people with lumbar spinal stenosis.
-
Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients
This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.
-
Lower-limb rehabilitation robot training with nutrition education for sarcopenia
In adults aged 60 and older with sarcopenia, this study tests whether adding robot-assisted leg training to nutrition education can improve muscle mass and walking ability compared with usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.